Back
Cartesian Therapeutics 10K Form
Sell
25
RNAC
Cartesian Therapeutics
Last Price:
12.91
Seasonality Move:
-10.23%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RNAC News And Ratings
See the #1 stock for the next 7 days that we like better than RNAC
RNAC Financial Statistics
Sales & Book Value
Annual Sales: | $26M |
---|---|
Cash Flow: | $-16.03M |
Price / Cash Flow: | 0 |
Annual Sales: | $-5.69 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -53.46000 |
---|---|
Net Income (TTM): | $-229.65M |
Gross Margin: | -- |
Return on Equity: | 0% |
Return on Assets: | -93.85% |
Cartesian Therapeutics Earnings Forecast
Key Cartesian Therapeutics Financial Ratios
- The Research & Development expenses have been 276.26% of Revenue.
- The Interest Expense is -1.29% of Operating Income.
- The Net Earning history of RNAC is -844.91% of Total Revenues.
- Per Share Earnings over the last 10 years have been positive in 6 years.
Cartesian Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | RNAC |
Website: | cartesiantherapeutics.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 4.78 |
Quick Ratio: | 4.7 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
RNAC Technical Analysis vs Fundamental Analysis
Sell
25
Cartesian Therapeutics (RNAC)
is a Sell
Is Cartesian Therapeutics a Buy or a Sell?
-
Cartesian Therapeutics stock is rated a Sell
The current Cartesian Therapeutics [RNAC] share price is $12.98. The Score for RNAC is 25, which is 50% below its historic median score of 50, and infers higher risk than normal.